BCPS BCPS Cardiovascular & Specialty Pharmacotherapy 2

Question 1

Which antiarrhythmic drug class works primarily by blocking sodium channels and is classified as a Class IC agent?

Accepted Answer

Flecainide

Answer

Flecainide is a Class IC antiarrhythmic that markedly slows conduction by blocking sodium channels, with minimal effect on repolarization.

Question 2

A patient with type 2 diabetes and established cardiovascular disease (atherosclerotic CVD) should receive which antidiabetic agent to reduce major cardiovascular events?

Accepted Answer

GLP-1 receptor agonist (e.g., liraglutide, semaglutide)

Answer

GLP-1 receptor agonists with proven CVD benefit (liraglutide, semaglutide, dulaglutide) are recommended in T2D patients with established ASCVD per ADA guidelines.

Question 3

Which anticoagulant is preferred for treatment of venous thromboembolism (VTE) in a patient with cancer?

Accepted Answer

Low molecular weight heparin or DOAC (edoxaban/rivaroxaban)

Answer

Current guidelines recommend LMWH or cancer-specific DOACs (edoxaban, rivaroxaban) for cancer-associated VTE due to reduced recurrence compared to warfarin.

Question 4

A patient presents with acute decompensated heart failure (ADHF) with signs of congestion. Which IV diuretic is first-line to relieve pulmonary edema?

Accepted Answer

IV furosemide

Answer

IV furosemide is the first-line agent for acute volume overload in ADHF due to its rapid onset and potent natriuretic effect within minutes of administration.

Question 5

A patient on warfarin for atrial fibrillation has an INR of 7.5 with no active bleeding. What is the most appropriate management?

Accepted Answer

Hold warfarin, administer oral vitamin K 2.5 mg

Answer

For an elevated INR (5-10) without bleeding, holding warfarin and administering low-dose oral vitamin K (1-2.5 mg) is recommended to prevent over-reversal.

(BCPS) Board Certified Pharmacotherapy Specialist Practice Test

(BCPS) Board Certified Pharmacotherapy Specialist Practice Test

BCPS BCPS Cardiovascular & Specialty Pharmacotherapy 2